x 

Cart empty
Login Form
AcyMailing Module
To subscribe to our newsletters, please complete the form below

These are clinical trials registered on the ClinicalTrial.gov website:

1. Quality of Life Study for Sickle Cell Patients Treated With Jobelyn (Sorghum Bicolor Extract)

ClinicalTrials.gov Identifier:
NCT01704794

The purpose of this study is to determine the antioxidant effect of prolonged use of sorghum bicolor (jobelyn) to increase the level of plasma superoxide dismutase and glutathione reductase in patients with sickle cell disease and to determine if there is any improvement in the quality of life of the patients.

2. The Efficacy of Jobelyn (Sorghum Bicolor Extract)in the Treatment of Sickle Cell Anemia -

ClinicalTrials.gov Identifier:
NCT01703104

The primary objective is to determine if there is a significant increase in the haematocrit value of patients on Jobelyn and standard therapy compared to those on standard therapy alone.

3. The Safety and Effectiveness of Jobelyn in Pre-operative Management of Anaemia in Gynaecological Patients

ClinicalTrials.gov Identifier:
NCT01670955

PROTOCOL FOR THE STUDY OF THE SAFETY AND EFFICACY OF JOBELYN, IN THE PREOPERATIVE MANAGEMENT OF ANAEMIA IN GYNAECOLOGICAL PATIENTS

4.The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients

ClinicalTrials.gov Identifier:
NCT01936064

To determine the effective functionality/potency of Jobelyn as an immunologic and haematologic booster in Breast cancer patients (start-off), thus improving the outlook and the quality of life of such patients generally

5.  Efficacy of Jobelyn™ Consumption on Hemoglobin Levels in a Borderline Anemic Population

ClinicalTrials.gov Identifier:
NCT01828060

The purpose of this study is to evaluate the timing and magnitude of improvements to red blood cell health associated with consumption of Jobelyn™.

6. Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia

ClinicalTrials.gov ID: NCT02240173

Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia

 

You are visitor No
790820
TodayToday52
YesterdayYesterday228
This_WeekThis_Week322
This_MonthThis_Month5641
All_DaysAll_Days790820
Highest 03-29-2017 : 2657
Guests 19
to this site